# A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer

Source: https://onco.cc/trials/nct05859750/  
OnCo record `nct05859750` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Cadonilimab, Gemcitabine, Leucovorin (folinic acid) and Oxaliplatin in pancreatic ductal adenocarcinoma, run by Akeso, now recruiting.

## Summary

A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer is a phase 2 interventional study registered as NCT05859750 by Akeso, with 78 participants planned, started 2023-05-25 and due to reach its primary completion in 2025-06. Interventions recorded: AK104, Gemcitabine, Nab-Paclitaxel, Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate and Oxaliplatin + Irinotecan + 5-Fluorouracil/Leucovorin.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05859750
- Phase: 2
- Setting: A Multicenter, Open-label, Phase II Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Combination With Chemotherapy as First-line Treatment in Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer
- Sponsor: Akeso
- Enrolled: 78

## Sources

- ClinicalTrials.gov NCT05859750: https://clinicaltrials.gov/study/NCT05859750

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- drugs: [Cadonilimab](https://onco.cc/drugs/cadonilimab/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Leucovorin (folinic acid)](https://onco.cc/drugs/leucovorin/), [Oxaliplatin](https://onco.cc/drugs/oxaliplatin/)
- companies: [Akeso](https://onco.cc/companies/akeso/)

---
JSON: https://onco.cc/api/v1/entities/nct05859750.json